Inventor · disambiguated record
Hong Shen
Also filed as: SHEN HONG · SHEN HONG C
50 granted patents·48 pending applications·414 citations·filing 2000–2025
98Inventor score
Top patents by PatentIndex Score
98 records- 0195US11008395B2Antibodies against IL-7R alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2020·Granted May 18, 2021·5 cites·25 claims
- 0294US9447086B26-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2013·Granted Sep 20, 2016·34 cites·5 claims
- 0394US7858643B2Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitorsAGOURON PHARMA·Filed 2005·Granted Dec 28, 2010·28 cites·2 claims
- 0493US9233978B26-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2015·Granted Jan 12, 2016·18 cites·23 claims
- 0593US8106197B2Aminoheteroaryl compounds as protein kinase inhibitorsCUI JINGRONG JEAN·Filed 2006·Granted Jan 31, 2012·48 cites·11 claims
- 0693US6677368B24-aryl substituted indolinonesSUGEN INC·Filed 2001·Granted Jan 13, 2004·72 cites·20 claims
- 0792US10596173B2Combination therapy of an HBV capsid assembly inhibitor and an interferonHOFFMANN LA ROCHE·Filed 2018·Granted Mar 24, 2020·10 cites·25 claims
- 0892US7230098B2Aminoheteroaryl compounds as protein kinase inhibitorsSUGEN INC·Filed 2004·Granted Jun 12, 2007·73 cites·15 claims
- 0990US10081627B26-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2015·Granted Sep 25, 2018·9 cites·30 claims
- 1089US10428069B26-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2018·Granted Oct 1, 2019·6 cites·21 claims
- 1188US11098080B2Peptide macrocycles against Acinetobacter baumanniiHOFFMANN LA ROCHE·Filed 2018·Granted Aug 24, 2021·3 cites·16 claims
- 1288US7030097B1Controlled nucleic acid delivery systemsCORNELL RES FOUNDATION INC·Filed 2000·Granted Apr 18, 2006·33 cites·47 claims
- 1387US7732604B2Triazolopyrazine derivativesPFIZER·Filed 2007·Granted Jun 8, 2010·11 cites·11 claims
- 1484US10030047B2Peptide macrocycles against acinetobacter baumanniiHOFFMANN LA ROCHE·Filed 2016·Granted Jul 24, 2018·2 cites·51 claims
- 1584US9260439B2Dihydropyrrolopyrimidine derivativesPFIZER·Filed 2015·Granted Feb 16, 2016·3 cites·18 claims
- 1683US9890167B2Pyrazine compounds for the treatment of infectious diseasesHOFFMANN LA ROCHE·Filed 2016·Granted Feb 13, 2018·4 cites·50 claims
- 1783US8916593B2Alkoxy-substituted 2-aminopyridines as ALK inhibitorsBUNNAGE MARK EDWARD·Filed 2011·Granted Dec 23, 2014·8 cites·5 claims
- 1882US8933113B2Mineralocorticoid receptor antagonistsCRESPO ALEJANDRO·Filed 2012·Granted Jan 13, 2015·11 cites·17 claims
- 1982US8785632B2Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitorsCUI JINGRONG JEAN·Filed 2012·Granted Jul 22, 2014·5 cites·4 claims
- 2080US9790230B22-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivativesHOFFMANN LA ROCHE·Filed 2017·Granted Oct 17, 2017·3 cites·10 claims
- 2180US9266904B26-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2014·Granted Feb 23, 2016·5 cites·23 claims
- 2279US9758530B26-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2016·Granted Sep 12, 2017·3 cites·14 claims
- 2379US9284301B2Soluble guanylate cyclase activatorsSCHMIDT DARBY·Filed 2011·Granted Mar 15, 2016·9 cites·4 claims
- 2478US2024417478A1Antibodies against il-7r alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2577US9840501B2Morpholin-pyridine derivativesHOFFMANN LA ROCHE·Filed 2016·Granted Dec 12, 2017·2 cites·12 claims
- 2676US8785634B2Spiropiperidine prolylcarboxypeptidase inhibitorsDING FA-XIANG·Filed 2011·Granted Jul 22, 2014·6 cites·15 claims
- 2775US12247036B2Tricyclic compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2024·Granted Mar 11, 2025·0 cites·27 claims
- 2875US11713327B2Heteroaryl heterocyclyl compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2019·Granted Aug 1, 2023·1 cites·17 claims
- 2974US12351575B26-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2019·Granted Jul 8, 2025·0 cites·13 claims
- 3071US11919962B2Antibodies against IL-7R alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·0 cites·29 claims
- 3171US8455520B2Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatmentCOLLETTI STEVEN L·Filed 2008·Granted Jun 4, 2013·1 cites·21 claims
- 3268US12012466B2Peptide macrocycles against Acinetobacter baumanniiHOFFMANN LA ROCHE·Filed 2021·Granted Jun 18, 2024·0 cites·5 claims
- 3368US2025257075A1Macrocyclic inhibitors of kras for the treatment of cancerHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 3463US2025206761A1Haloindole macrocyclic compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3562US6861418B24-aryl substituted indolinonesSUGEN INC·Filed 2003·Granted Mar 1, 2005·1 cites·20 claims
- 3660US2014288086A1Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitorsCUI JINGRONG JEAN·Filed 2014·Application pending·0 cites
- 3759US2025376482A1Tricyclic compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 3857US12503471B2Triazatricycle compounds for the treatment of autoimmune diseaseHOFFMANN LA ROCHE·Filed 2020·Granted Dec 23, 2025·0 cites·15 claims
- 3957US2025163072A1Macrocyclic compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4056US12012390B2Flavone compounds for the treatment and prophylaxis of hepatitis B virus diseaseHOFFMANN LA ROCHE·Filed 2019·Granted Jun 18, 2024·0 cites·19 claims
- 4156US2020339603A1Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infectionHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4256US2020276198A1Combination therapy of an hbv capsid assembly inhibitor and an interferonHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4355US2025194649A1Fatty acid amides and their use as flavor modifiersFIRMENICH & CIE·Filed 2023·Application pending·0 cites
- 4455US2021221832A1Substituted pyridoindoles for the treatment and prophylaxis of bacterial infectionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4554US2021317141A1Oxopyrido[1,2-a]pyrimidine compounds for the treatment and prophylaxis of bacterial infectionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4654US2021309657A1Tricyclic compounds for the treatment and prophylaxis of bacterial infectionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4754US2021309658A1Aryl compounds for the treatment and prophylaxis of bacterial infectionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4854US2011003849A1Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatmentSHEN HONG·Filed 2009·Application pending·0 cites
- 4953US9403807B2Mineralocorticoid receptor antagonistsMERCK SHARP & DOHME·Filed 2014·Granted Aug 2, 2016·0 cites·5 claims
- 5053US2021323981A1Free amino compounds for the treatment and prophylaxis of bacterial infectionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
Showing the top 50 of 98 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hong Shen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →